Corrigendum to "In vitro susceptibility to the pro-apoptotic effects of TIMP-3 gene delivery translates to greater in vivo efficacy versus gene delivery for TIMPs-1 or -2" [Lung Cancer 53 (3) (September 2006) 273–284]. (November 2016)